Answers are grounded in this paper and cite their sources.
Phase 3 trial demonstrates long-term survival benefits of tislelizumab and chemotherapy in advanced lung cancer, suggesting it as a viable option.
Introduction Squamous nonsmall cell lung cancer (sq-NSCLC) is challenging to treat, with shorter survival when compared with other NSCLC subtypes. Tislelizumab has demonstrated efficacy when combined with chemotherapy for sq-NSCLC. We report 4-year follow-up results from the phase 3 randomized RATIONALE-307 trial evaluating tislelizumab plus chemotherapy as first-line treatment for advanced or metastatic sq-NSCLC. Methods Patients with treatment-naive advanced or metastatic sq-NSCLC were randomized to receive tislelizumab plus paclitaxel/carboplatin (arm A), tislelizumab plus nab-paclitaxel/carboplatin (arm B), or paclitaxel/carboplatin alone (arm C) until disease progression/intolerable toxicity. Crossover was permitted from arm C to tislelizumab monotherapy. The primary end point was progression-free survival (PFS) per independent review. Key secondary end points included overall survival (OS) and safety. Results At median OS follow-up of 44.8 months, tislelizumab plus chemotherapy demonstrated durable survival benefit. Median PFS was 7.7 months (95% confidence interval [CI] 6.7–9.9) in arm A, 9.5 months (95% CI 7.4–10.1) in arm B, and 5.5 months (95% CI 4.2–5.6) in arm C. Median OS was 26.1 months (95% CI 19.0–33.8) in arm A, 23.3 months (95% CI 18.8–26.4) in arm B, and 19.4 months (95% CI 16.0–23.4) in arm C. The 4-year OS rates were 32.2%, 26.0%, and 19.2% for arms A, B, and C, respectively. Crossover occurred in 58.7% of patients from arm C. OS and PFS benefits were observed across most subgroups. Grade ≥ 3 treatment-emergent adverse events occurred in 89.2%, 89.0%, and 84.6% of patients in arms A, B, and C, respectively. No new safety signals emerged. Conclusions At 4-year follow-up, patients with advanced sq-NSCLC who received tislelizumab plus chemotherapy experienced long-term OS and PFS benefits versus chemotherapy alone, despite high crossover rates. The combination was well-tolerated with no new safety concerns. This regimen may be a promising first-line treatment option for patients with advanced or metastatic sq-NSCLC. Trial Registration ClinicalTrials.gov NCT03594747.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: